The trial was divided into two parts: Part A primarily assessing Epidiolex’s safety and target dose, and Part B evaluating its anti-epileptic effectiveness at the chosen target dose.

This study reports on the safety results and preliminary pharmacokinetics of Part A, evaluated in a group of children with Dravet syndrome.

A total of 34 patients, between 4 and 10 years old recruited in the U.S. and U.K., were randomized to receive Epidolex, at 5, 10, or 20 mg/kg/day, or placebo twice daily for 21 days. The trial included a four-week initial observation period, three weeks of treatment, a 10-day tapering-off period, and a final follow-up four weeks after the end of treatment.

Safety was assessed through several measurements, including vital signs, electroencephalograms, seizure frequency, and suicidal thoughts, which were all found to be in normal ranges and without meaningful changes in the treatment group.

Participants on Epidiolex had more adverse events than those in the placebo group, but the treatment was generally well-tolerated at all three doses tested. The most common adverse events associated with Epidiolex, occurring in three or more patients, were fever, somnolence, decreased appetite, sedation, vomiting, ataxia, and abnormal behavior.

Six children treated with both Epidiolex and valproate had elevated transaminases — enzymes that can indicate liver damage — but none met the criteria for drug-induced liver injury and all six recovered.

No interactions were observed between Epidiolex and other anti-epileptic drugs also being taken by patients, except for an increase in N-desmethylclobazam levels, a byproduct of clobazam. This interaction did not occur in patients who were also on stiripentol, likely due to its inhibitory effect on the liver enzyme CYP2C19, but additional studies on drug distribution and drug-drug interactions are needed.

Since all three doses of Epidiolex were generally well-tolerated in Part A, researchers chose 20 mg/kg/day as the appropriate dose for Part B, which was a Phase 3 randomized trial.

During this part, the effectiveness of Epidiolex as an add-on therapy to anti-epileptic treatment was evaluated. Subjects received the investigational product for 14 weeks, including a dose-escalating period, followed by a 12-week maintenance period, during which the frequency of monthly convulsive seizures was measured.

Results from this part of the CARE1 trial (NCT02091375), previously published in the New England Journal of Medicine,demonstrated that a daily dose of 20 mg/kg in addition to standard anti-epileptic treatment over 14 weeks led to a 39% decrease in patient seizure frequency, compared with 13% in the placebo group.

Epidiolex is also currently being tested by GW in other Phase 3 trials for severe and treatment-resistant epilepsy syndromes including Dravet and Lennox-Gastaut syndrome.

GW has launched a Phase 3 trial, CARE2 (NCT02224703), investigating the safety and effectiveness of Epidiolex in children and young adults with Dravet syndrome. The randomized trial is currently recruiting up to 150 participants ages 2 to 18 at multiple centers in the United States and Europe.

Treatment with Epidiolex also recently showed promising results in a Phase 3 trial for Lennox-Gastaut syndrome (NCT02224690). Compared with patients receiving placebo, those on Epidiolex had a stronger reduction in monthly drop seizures — 22% versus 44%, respectively. Reductions in drop seizures were observed in the first month of Epidiolex treatment and maintained thereafter.

Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.

Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.

Disclaimer:

Dravet Syndrome News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Pin It on Pinterest

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more